The largest community of pharma leaders

Oncology® Welcomes Julie M. Vose, M.D., MBA, and Howard S. Hochster, M.D., FACP, as Co-Editors in Chief

CRANBURY, N.J.–()–Oncology® and CancerNetwork®, a multispecialty platform focused on bringing practical, peer-reviewed content that can affect how oncologists, oncology nurses, and other relevant health care professionals treat their patients, are pleased to announce the appointment of Julie M. Vose, M.D., MBA, and Howard S. Hochster, M.D., FACP, as co-editors in chief of the journal Oncology®.

“We are extremely grateful to have Drs. Vose and Hochster join the Oncology® team as co-editors in chief,” said Mike Hennessy Jr., president and CEO of MJH Life Sciences™, parent company of Oncology®. “With decades of combined clinical expertise, we are eager to see how their contribution and council will help steer the publication as it continues to grow as a dynamic resource for oncology professionals.”

Dr. Vose has been a member of the faculty at University of Nebraska Medical Center (UNMC) since she completed her fellowship there in 1990. She currently serves as the chief of the oncology/hematology division in the Department of Internal Medicine at UNMC and Oncology Chief for Nebraska Medicine. Known internationally as a leading expert in the treatment of patients with lymphoma, Dr. Vose is actively involved in various novel clinical trials for patients with hematologic malignancies.

Hochster, a graduate of the Yale School of Medicine, completed an internship, residency and fellowship in Hematology-Oncology at NYC Health + Hospitals/Bellevue and NYU Langone Medical Center. Hochster is a part of the Rutgers Cancer Institute of New Jersey, serving as the associate director for clinical research and director of gastrointestinal (GI) oncology. He also serves as the director of oncology research at RWJBarnabas Health. Hochster served for eight years as a member of the NCI Colon Task Force and also as a member of the NCI GI Steering for 6 years. Also recently serving as GI Committee chair of the SWOG cooperative group, he has played an integral role in many of the studies that have set standards for pioneering new treatments in cancer care.

“We’re looking forward to the wealth of knowledge both Drs. Vose and Hochster will bring to our network of health care professionals in the oncology space,” said Kristie Kahl, editorial director of Oncology®. “Working together with our co-editors in chief, we look to provide our network with the most up-to-date, easily-digestible content surrounding diagnostics, treatment and more.”

As co-editors in chief, Drs. Vose and Hochster will aid Oncology® in delivering top-tier content and broaden the variety of oncology topics covered. Now backed by their guidance, the publication will delve deeper into topics such as women’s cancers, genitourinary cancer, gastrointestinal cancer, lung cancer, hematologic malignancies and immunotherapy.

For more information about Oncology® and CancerNetwork®, click here.

About Oncology® and CancerNetwork®

Oncology® and CancerNetwork® provide insights from Key Opinion Leaders in oncology, with articles, peer perspectives, videos, podcasts and interactive content that translates into clinical application for today’s practicing oncologist. Oncology® and CancerNetwork® are brands of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.


Recent Articles